 Hi, I'm Daniela Gornieri. I work at the Center for Advances by Materials for Healthcare of the Institute of Italian and Technology in Naples, Italy. And he is Michael Littmar from the Department of Pharmacy of the University of Naples Pedagogical Development. In this video I would like to introduce you our work paper entitled Tumor-Activated Project Rejugated Non-Particles with Clearable Domains for Safety and Absorbing Recently accepted for publication by the Faculty of Engineering Journal. Here we report on the design of polystyrene nanoparticles for the on-demand delivery of doxorubicin which is a widely employed anticancer drug. The produced nanoparticles release their drug payload in response to specific physiological changes naturally occurring within tumors. This is crucial since systemically administered anticancer drugs lack specificity and after repeated administration generate severe toxic side effects to healthy tissues and organs. Therefore, the idea was to produce nanoparticles which are non-toxic to non-target tissues by elisting a selected drug release within the target tissue so as to improve the drug of toxicological profile. To this aim we exploited doxorubicin release triggered by the action of Matrix-Metallococcus to enzyme which is overexpressed in the extracellular matrix of tumors and is involved in many catalytic activities related with tumor progression. Here we report on the synthesis of a tumor-activated protract composed of doxorubicin attached to polystyrene glycol through two Matrix-Metallocotase two clipable peptides namely a amy. Both peptides contain the release-inducing sequence which is highly sensitive to Matrix-Metallocotase action. The tumor-activated protracts were then tethered on the surface of 200 nanometer caboxymodified polystyrene amy. The resultant that conduit the amy will characterize for their imitial release pressures at 37 degrees different MMP2 concentrations to identify the minimum reactive enzyme dose response. In particular in the absence of the enzyme, doxorubicin was released very slowly. On the contrary, MMP2 presence within the release medium triggered much faster rapid dose release which reached at the top after approximately 10 hours. The percentage of release doxorubicin was 40-50 fold higher in the case of tap-pin non-particles and 78 fold higher for tap-pin non-particles compared to the case of MMP2 free release medium. It must be also noticed that in all cases the enzyme effects reached the saturation about 20 nanometer MMP2 concentration. The specific action of tap-conjugated non-particles due to the release of free dox from the non-particles was also confirmed by cytotoxicity experiments carried out on three different cell types. Indeed the cytotoxic effect of tap- non-particles was observed on both tumor and primary cells only happened cleavage by MMP2 enzyme. Furthermore, cytotoxicity was higher for non-particles functionalized with tap-p compared to tap-a in agreement with the observable release kinetics. Confidant microscope observations demonstrated the cellular optical dox after two days of innovation with MMP2 treated tap-non-particles. In particular, both the diffuse and spotted fluorescence was noticed within the cytoplasm and the nucleus thus indicated the partial release of free dox. Interestingly, also for cells innovated non-retreated tap-non-particles and intracellular fluorescence was detected. However, in this case no detectable signals of free diffuse or no pure dox was observed within the cell, clearly indicating an induced cytotoxic effect of dox when the drug is covalently bound to non-particles. This biotechnological approach holds promise in the field of the safe transport of cytotoxic drugs to tumors, thereby reducing the unwanted cytotoxicity towards healthy tissues and tumors. Future development of this work will deal with the translation of this technology to the production of non-particles for the on-demand drug release. The non-particles will be made up of biodegradable FDR-proof materials. We wish to thank all the providers and hope you will enjoy your reading our paper. Thank you. Thank you.